

RESEARCH

Open Access



The association between serum adropin and carotid atherosclerosis in patients with type 2 diabetes mellitus: a cross-sectional study

Wen Wei^{1,2}, Hui Liu³, Xiuping Qiu¹, Jushun Zhang¹, Jianqing Huang¹, Hangju Chen¹, Shuilin Qiu¹, Ruiyu Lin⁴, Shihai Li^{5*} and Mei Tu^{1*}

Abstract

Background: Adropin, a newly-identified energy homeostasis protein, has been implicated in the maintenance of metabolic homeostasis and insulin sensitivity. This study attempts to measure the association between serum adropin and carotid atherosclerosis in patients with type 2 diabetes mellitus (T2DM).

Methods: This cross-sectional study was performed in 503 hospitalized patients with T2DM. Serum adropin level was measured by a sandwich enzyme-linked immunosorbent assay. The carotid atherosclerosis was assessed by color Doppler sonography. The association between adropin and carotid atherosclerotic plaque was tested by logistic regression model. The effect of adropin on carotid intimal-medial thickness (CIMT) was estimated using linear regression model.

Results: Overall, 280 (55.7%) patients had carotid atherosclerotic plaque. The risk of carotid atherosclerotic plaque decreased with the increment of serum adropin level (adjusted odds ratio [aOR], 0.90; 95%CI: 0.81–0.99) in patients with T2DM. Serum adropin (Standardized $\beta = -0.006$, $p = 0.028$) was also independently protective factor for CIMT in patients with T2DM.

Conclusion: In patients with T2DM, high serum adropin level was correlated with a decreased risk of carotid atherosclerosis in T2DM patients. Low circulating level of adropin may promote carotid atherosclerosis.

Keywords: Adropin, Carotid atherosclerosis, Type 2 diabetes mellitus

Background

Cardiovascular disease (CVD), including coronary artery disease (CAD), stroke, and peripheral artery disease (PAD), is a well-known leading cause of mortality in diabetic patients [1]. Atherosclerosis is one of the major underlying factors [2]. Although metabolic disorder

in diabetes has been proved to be an important mediator to initiate and promote atherosclerosis [3], there are still some potential related molecules that may affect the development of atherosclerosis in diabetes. Exploration of related molecules may provide new biomarkers or therapeutic targets for atherosclerosis in diabetes.

Adropin is a bioactive protein encoded by the energy homeostasis associated gene (Enho) that is expressed in the liver and brain. Adropin contains 76 amino acids and has a molecular weight of 4.5 kDa [4]. Adropin regulates various signaling pathways to enhance insulin sensitivity, glucose metabolism, endothelial function, and motor coordination. In neurons, adropin binds to contactin 6

*Correspondence: 13959002329@139.com; Lysytm@qq.com

¹ Department of Endocrinology, Fujian Longyan First Hospital, Longyan First Affiliated Hospital of Fujian Medical University, Longyan 364000, China

⁵ Department of Anesthesia, Fujian Longyan First Hospital, Longyan First Affiliated Hospital of Fujian Medical University, Longyan 364000, China
Full list of author information is available at the end of the article



to activate Notch1 signaling and regulate brain development. In addition, adropin activates mitogen-activated protein kinase (MAPK) signaling in endothelial cells through either vascular endothelial growth factor receptor 2 (VEGFR2) or in cardiomyocytes through G protein-coupled receptor 19 (GPR19) [5]. Adropin has an important role in maintaining energy homeostasis and insulin sensitivity, which has been proved to attenuated the development of atherogenesis in animal experiment [6–8]. Low serum adropin level was also associated with stable angina pectoris, acute myocardial infarction and the severity of coronary atherosclerosis [9–14]. Fujie S et al. also found a negative correlation between serum adropin level and carotid arterial stiffness [15]. However, no study has examined the relationship between circulating adropin level and carotid atherosclerosis in diabetic patients.

Therefore, we aim to assess the association between serum adropin and carotid atherosclerosis in patients with type 2 diabetes mellitus (T2DM).

Methods

Study population and data sources

Our study was cross-sectional and the data were extracted from the electronic clinical management records system of Longyan First Affiliated Hospital of Fujian Medical University. Totally, 503 adult patients (≥ 18 years of age) with T2DM hospitalized for either diabetic complications screening or poor blood glucose control were continuously observed from July 2018 to June 2019. Patients with ketoacidosis, hyperosmolar status, acute severe infection, renal diseases on hemodialysis, autoimmune disease, malignant cancer, severe cardiac insufficiency, and incomplete clinical parameters were eliminated. The study was approved by the ethics committee of Longyan First Affiliated Hospital of Fujian Medical University (approval number LY-2017–068), and written informed consent was obtained from all participants.

Data collection

We recorded information about all participants, such as smoking habit, duration of diabetes, history of diabetic complications, hypertension, CAD and stroke, administered drugs including insulin or oral antidiabetic drugs (OADs), antihypertensive agents (AHAs), statins and aspirin, laboratory test results and other clinical variables including height, weight, waist circumference (WC) and blood pressure (BP). Venous blood samples were collected in the early morning after overnight fasting.

Hypertension was defined as current treatment for hypertension, or systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg. Body mass index

(BMI) was calculated by dividing weight (kg) by the square of height (m). Homeostatic model assessment-insulin resistance (HOMA-IR) was calculated using the following formula: fasting blood glucose (mmol/l) \times fasting plasma insulin (mU/l)/22.5. Estimated glomerular filtration rate (eGFR) value was calculated based on serum creatinine (Scr) level using the Modification of Diet in Renal Disease (MDRD) formula.

Measurement of adropin

Samples of venous blood were collected after overnight fasting, and stored at -80°C prior to analyses. Serum adropin level was measured by a commercial enzyme-linked immunosorbent assay (ELISA) kit (Nanjing Camilo biological engineering Co., Ltd., Jiangsu, China), which give intra-batch and inter-batch variations were 8% and 12%, respectively. The lowest level of adropin ELISA assay was 0.5 ng/ml. Duplicate measurements were obtained for all samples.

Ultrasonography measurements

Ultrasonography was performed by two experienced sonographers under a standardized protocol. Color Doppler sonography was performed with a high frequency linear transducer (5–12 MHz, Epiq5, Philips Ultrasound, Bothell, WA). All subjects were examined in a supine position, with a slight rotation of the neck to the contralateral side with the minimal tension of the cervical muscles. Carotid arteries were examined bilaterally at the common carotid arteries, the bifurcation, the external carotid arteries, and the internal carotid arteries from transverse and longitudinal orientations and were scanned in the anterolateral, posterolateral and mediolateral directions to assess the presence of atherosclerotic plaque and stenosis and measure intima-media thickness (IMT).

Atherosclerotic plaque was defined as a focal thickening of the intima-media complex encroaching into the arterial lumen by at least 0.5 mm or involving 50% of the surrounding IMT, or a focal thickening from the intima-lumen interface to the media-adventitia interface of over 1.5 mm [16]. Carotid atherosclerotic plaque was defined as the presence of atherosclerotic plaques in any of the aforementioned carotid arteries segments [17, 18]. Carotid intimal-medial thickness (CIMT) is perceived as common carotid IMT, which is calculated as the mean of the single maximum CIMT measurements that are measured from different segments of the carotid artery. When plaques are present in a segment, the maximal value is by definition at the maximum height of the plaque [16]. Mean CIMT was defined as the mean values of bilateral CIMTs.

Statistical analyses

For continuous variables, normality was checked. If the data showed a normal distribution, variables were given as mean \pm standard deviation, and two-sample independent t-test was used to compare differences among groups. If the data were not distributed normally, the Mann–Whitney U non-parametric test was employed and variables were expressed as median with interquartile range. For categorical variables, they were expressed by absolute numbers and percentages. Chi-square test was used to evaluate the differences in categorical variables.

Restricted cubic splines were used to detect the association between the serum adropin level and carotid atherosclerotic plaque or mean CIMT. The relationship between adropin and carotid atherosclerotic plaque was assessed by univariable and multivariable logistic regression. The effect of serum adropin level on CIMT was estimated using linear regression model before and after adjusting for confounding factors. Variables decided to enter the multivariable model were carefully selected based on variables associated with known risk factors or variables with p -value < 0.05 in baseline or in univariable regression analysis.

All analyses were performed with R software (version 4.0.5; R Foundation for Statistical Computing, Vienna, Austria). A two-sided p -value < 0.05 indicated significance for all analyses.

Results

Clinical characteristics

Totally, 503 subjects including 297 men and 206 women were enrolled in this study. Overall, the prevalence rate of carotid atherosclerotic plaque was 55.7%. The subjects were divided into two groups based on with or without carotid atherosclerotic plaque. There were no significant differences in the serum adropin level between the two groups (20.5 ± 4.0 vs. 20.6 ± 3.7 ng/ml $p = 0.763$) (Table 1).

Compared with patients without carotid atherosclerotic plaque, patients with carotid atherosclerotic plaque were likely to be older (61.5 ± 10.1 years vs. 51.6 ± 9.8 years, $p < 0.001$). These patients demonstrated longer duration of diabetes [8 (3, 11) years vs. 4 (0, 10) years, $p < 0.001$] and higher incidences of diabetic nephropathy (DN) (24.4% vs. 9.3%, $p < 0.001$), diabetic retinopathy (DR) (27.7% vs. 13.9%, $p = 0.005$), and hypertension (46.8% vs. 33.6%, $p = 0.004$) than patients without carotid atherosclerotic plaque. Patients with carotid atherosclerotic plaque showed higher BMI, WC, SBP, HOMA-IR and homocysteine (HCY) levels than patients without. The detailed patients' clinical characteristics are listed in Table 1.

Association between serum adropin and carotid atherosclerosis

A linear association (Nonlinear $p = 0.122$) between carotid atherosclerotic plaque and serum adropin level was indicated in our study populations: the higher the serum adropin level, the lower the incidence of carotid atherosclerotic plaque (Fig. 1). The risk of carotid atherosclerotic plaque significantly decreased with the increment of serum adropin level (adjusted odds ratio [aOR], 0.90; 95% CI: 0.81–0.99) in patients with T2DM. Moreover, when the first tertile was used as the reference category, the adjusted association with risk was also significant for both the second and third tertile of adropin (Table 2).

Restricted spline curve also showed that the higher the serum adropin level, the less the CIMT (Fig. 2). After adjusted for age, gender, smoke, BMI, WC, duration of diabetes, DN, hypertension, HOMA-IR, LDL-C, hs-CRP and HCY, linear regression analysis showed that serum adropin level (Standardized $\beta = -0.006$, $p = 0.028$) was independently protective factor for CIMT in patients with T2DM (Table 3).

Discussion

To our best knowledge, this present study was the first to evaluate the association between serum adropin and carotid atherosclerosis in patients with T2DM. The results showed that the risk of carotid atherosclerotic plaque and carotid artery intimal thickening decreased with the increment of serum adropin level. Low circulating level of adropin may be involved in promotion of carotid atherosclerosis.

It is well known that carotid atherosclerosis is a marker of systemic atherosclerosis and strong predictor of cardiovascular events [19–22]. Most seniors develop atherosclerosis as a function of age itself. Older diabetic patients with carotid atherosclerosis are often in high risk for CAD, PAD and/or cerebrovascular disease that further compromise functional capacity. The traditional risk factors such as age, smoke, diabetes, hypertension, dyslipidemia, obesity and insulin resistance are considered to be involved in the development of carotid atherosclerosis. Hcy and hs-CRP have been recognized as risk factors for atherosclerosis and cardiovascular diseases [23, 24]. Previous studies reported that low serum adropin level may be a risk factor or a potential predictor for developing coronary atherosclerosis [9–11]. Additionally, lower adropin level was associated with obesity, insulin resistance, hypertension and hs-CRP [7, 25–28]. Therefore, we adjusted for the known risk factors and statistically different factors, and then found the independently negative relationship between serum adropin level and

Table 1 Comparison of clinical characteristics between patients with and without carotid atherosclerotic plaque

Characteristic	Without carotid plaque (n = 223)	With carotid plaque (n = 280)	p-value
Demographic characteristics			
Age (years)	51.6 ± 9.8	61.5 ± 10.1	< 0.001
Male	133 (59.6)	164 (58.6)	0.880
WC (cm)	88.6 ± 9.2	89.9 ± 10.8	0.033
BMI (kg/m ²)	23.9 ± 3.1	24.8 ± 3.6	0.004
Medical history and Clinical condition			
Smoking history	70 (31.4)	103 (36.8)	0.242
Hypertension	75 (33.6)	131 (46.8)	0.004
SBP (mmHg)	134.4 ± 18.5	139.3 ± 19.3	0.004
DBP (mmHg)	83.9 ± 12.2	80.9 ± 12.2	0.006
Duration of diabetes (years)	4 (0, 10)	8 (3, 11)	< 0.001
DR	23 (13.9)	59 (27.7)	0.005
DPN	72 (55.0)	103 (57.2)	0.752
DN	15 (9.3)	51 (24.4)	< 0.001
Stroke	5 (2.2)	17 (6.1)	0.062
NAFLD	116 (58.0)	117 (50.2)	0.128
Laboratory examination			
Adropin (ng/ml)	20.5 ± 4.0	20.6 ± 3.7	0.763
FBG (mmol/L)	9.2 ± 3.4	9.1 ± 3.5	0.852
2hPBG (mmol/L)	13.1 ± 4.8	13.2 ± 5.1	0.751
HbA1c (%)	10.1 ± 2.5	10.7 ± 2.7	0.056
HOMA-IR	13.8 (7.6, 27.7)	17.9 (8.7, 32.3)	0.023
TG (mmol/L)	2.2 ± 1.8	1.9 ± 1.5	0.057
TC (mmol/L)	5.0 ± 1.2	4.9 ± 1.2	0.192
HDL-C (mmol/L)	1.2 ± 0.4	1.3 ± 0.5	0.167
LDL-C (mmol/L)	3.2 ± 1.0	3.1 ± 1.1	0.305
eGFR (ml/min/1.73 m ²)	124.0 ± 38.1	106.8 ± 36.0	< 0.001
UA (μmol/L)	344.8 ± 92.4	345.0 ± 91.3	0.981
hs-CRP (mg/L)	1.2 (0.6, 2.3)	1.4 (0.7, 2.9)	0.090
HCY (μmol/L)	10.6 ± 3.3	11.4 ± 3.8	0.018
Administered drugs			
Insulin	36 (16.1)	58 (20.7)	0.234
OADs	123 (55.4)	173 (62.5)	0.133
Statins	6 (2.7)	17 (6.1)	0.112

WC waist circumference, BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, DR diabetic retinopathy, DPN diabetic peripheral neuropathy, DN diabetic nephropathy, CAD coronary artery disease, NAFLD Nonalcoholic fatty liver disease, FBG Fasting blood glucose, 2h PBG 2 h postprandial blood glucose, HbA1c glycosylated hemoglobin, HOMA-IR homeostatic model assessment-insulin resistance, TG triglyceride, TC total cholesterol, HDL-C high density lipoprotein cholesterol, LDL-C low density lipoprotein cholesterol, eGFR estimated glomerular filtrationrate, UA uric acid, hs-CRP hypersensitive C-reactive protein, HCY homocysteine, OADs oral antidiabetic drugs

the risk of carotid atherosclerosis. However, serum adropin levels did not differ significantly between groups and the univariable analysis was not statistically significant. These results may be partly explained by a relatively small population in our study. Another possible reason is that there is some correlation between adropin and confounding factors such as obesity, and the true effect of adropin is concealed by the effect of confounding factors. After eliminating the influence of confounding factors

by multivariable analysis, the true effect of adropin on carotid atherosclerosis is revealed.

Atherosclerosis is a multifactorial and complex process involving endothelial dysfunction, vascular inflammation, vascular smooth muscle cells (VSMCs) proliferation, thrombus formation, monocytes infiltration and differentiation into macrophages, and the conversion of lesion-resident macrophages into foam cells [29]. The mechanism underlying the relationship between




Table 2 Logistic regression analysis for carotid atherosclerotic plaque

	Univariable		Multivariable	
	OR(95%CI)	p-value	aOR(95%CI)	p-value
adropin, continuous				
Per 1-point increment	1.01(0.96–1.06)	0.763	0.90(0.81–0.99)	0.034
adropin, categorical (Tertile 1 as reference)				
Tertile 2	1.15(0.75–1.78)	0.521	0.40(0.19–0.98)	0.039
Tertile 3	1.02(0.66–1.57)	0.936	0.30(0.12–0.74)	0.011

Adjusted for age, gender, smoke, BMI, WC, duration of diabetes, DN, hypertension, HOMA-IR, LDL-C, hs-CRP and HCY

BMI body mass index, WC waist circumference, DN diabetic nephropathy, HOMA-IR homeostatic model assessment-insulin resistance, LDL-C low density lipoprotein cholesterol, hs-CRP hypersensitive C-reactive protein, HCY homocysteine

adropin and atherosclerosis may be as follows. Adropin is involved in the endothelial function and the inhibition of atherosclerosis by up-regulating endothelial nitric oxide

synthase (eNOS) [30]. An in vitro laboratory experiment showed that endothelial cells treated with adropin exhibited greater proliferation, migration, capillary-like tube formation and up-regulation of the expression of eNOS [30]. Besides, the reduced circulating adropin concentration has an important correlate of metabolic disorders associated with insulin resistance and obesity, which are closely linked to the progression of atherosclerosis [6, 7, 31]. Adropin may be a potential anti-inflammatory protein and may play an important role in the prevention of atherosclerosis [32, 33].

Endothelial impairment and dysfunction caused by diabetic metabolic disorder has been confirmed as an important mediator in initiating and promoting atherosclerosis [3]. Our results further suggested that decreased adropin level will increase the risk of atherosclerosis in patients with T2DM. Since low serum adropin level and diabetes are both promoting atherosclerosis, their combination may lead to more severe atherosclerosis. Further studies are needed to investigate the causal relationship among adropin, diabetes and atherosclerosis.

Based on the mentioned studies it can be hypothesized that therapies addressing adropin could improve endothelial function, retard atherosclerosis, and




Table 3 Linear regression analysis for CIMT

	Univariable Standardized β (95%CI)	<i>p</i> -value	Multivariable Standardized β (95%CI)	<i>p</i> -value
Adropin, continuous				
Per 1-point increment	0.000(− 0.004 to 0.004)	0.938	− 0.006(− 0.011 to − 0.001)	0.028
adropin, categorical (Tertile 1 as reference)				
Tertile 2	0.005(− 0.032 to 0.041)	0.795	− 0.037(− 0.062 to − 0.002)	0.046
Tertile 3	− 0.015(− 0.052 to 0.022)	0.425	− 0.054(− 0.101 to − 0.008)	0.023

Adjusted for age, gender, smoke, BMI, WC, duration of diabetes, DN, hypertension, HOMA-IR, LDL-C, hs-CRP and HCY

CIMT carotid intimal-medial thickness, BMI body mass index, WC waist circumference, DN diabetic nephropathy, HOMA-IR homeostatic model assessment-insulin resistance, LDL-C low density lipoprotein cholesterol, hs-CRP hypersensitive C-reactive protein, HCY homocysteine

decrease the risk for the development of insulin resistance. Fujie et al. also found aerobic exercise training increased the levels of serum adropin and plasma oxidase, and concomitantly reduced arterial stiffness [15]. Given that carotid atherosclerosis is associated with an increased risk of cardiovascular disease and low serum adropin level may be involved in promotion of carotid atherosclerosis, adropin may thus be a useful agent in preventing atherosclerosis and its progression. In addition, measurement of serum adropin level may allow

clinicians to identify diabetic patients at elevated risk for carotid atherosclerosis.

Our study had several limitations. First, the cross-sectional design limited our ability to assess the cause-effect relationship between the serum adropin and carotid atherosclerosis. Second, this was merely a single-center study with a relatively small number of patients. The relationship between the risk of carotid atherosclerosis and adropin need to be confirmed in further larger prospective studies including nondiabetic population. Third, the

precise regulatory mechanism associated with adropin and carotid atherosclerosis and whether adropin may be a useful agent in preventing atherosclerosis require further investigation.

Conclusion

In the present study we found that the risk of carotid atherosclerosis decreased with the increment of serum adropin in patients with T2DM. Low circulating level of adropin may promote carotid atherosclerosis. Further studies revealing the immanent connection among adropin, diabetes and atherosclerosis may provide a novel biomarker for atherosclerosis in diabetic patients.

Abbreviations

AHAs: Antihypertensive agents; ACEI/ARB: Angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; BMI: Body mass index; CVD: Cardiovascular disease; CAD: Coronary artery disease; CIMT: Carotid intimal-medial thickness; CCB: Calcium channel blocker; DBP: Diastolic blood pressure; DR: Diabetic retinopathy; DPN: Diabetic peripheral neuropathy; DN: Diabetic nephropathy; ELISA: Enzyme-linked immunosorbent assay; eGFR: Estimated glomerular filtration rate; Enho: Energy homeostasis associated gene; eNOS: Endothelial nitric oxide synthase; FBG: Fasting blood glucose; GPR19: G protein-coupled receptor 19; HbA1c: Glycosylated hemoglobin; HOMA-IR: Homeostatic model assessment-insulin resistance; HDL-C: High density lipoprotein cholesterol; HCY: Homocysteine; hs-CRP: Hypersensitive C-reactive protein; IMT: Intima-media thickness; LDL-C: Low density lipoprotein cholesterol; MAPK: Mitogen-activated protein kinase; MDRD: Modification of Diet in Renal Disease; NAFLD: Nonalcoholic fatty liver disease; OADs: Oral antidiabetic drugs; PAD: Peripheral artery disease; Scr: Serum creatinine; SBP: Systolic blood pressure; T2DM: Type 2 diabetes mellitus; TG: Triglyceride; TC: Total cholesterol; UA: Uric acid; VEGFR2: Vascular endothelial growth factor receptor 2; VSMCs: Vascular smooth muscle cells; WC: Waist circumference; 2hPBG: 2Hours post-prandial blood glucose.

Acknowledgements

Not applicable.

Authors' contributions

Substantial contributions to the conception and design of the study (MT); data collection (XPQ, JSZ, JQH, HJC, SLQ, RYL); data analysis and/or interpretation of data for the work (WW, XPQ, JSZ); serum adropin measurement (HL); drafting of the work or revising it critically for important intellectual content (WW, SHL); final approval of the version to be published (all the authors).

Funding

This research was funded and supported by Fujian Provincial Natural Science Foundation (Grant number: 2018J01409) and Startup Fund for scientific research, Fujian Medical University (Grant number: 2017XQ1183).

Availability of data and materials

Data relevant to this study are available from the corresponding authors upon reasonable request.

Declarations

Ethics approval and consent to participate

The study was approved by the Research Ethics Committee of Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences. All participants provided written informed consent prior to enrolment.

Consent for publication

All authors support the submission to this journal.

Competing interests

The authors declare that they have no competing interests.

Author details

¹Department of Endocrinology, Fujian Longyan First Hospital, Longyan First Affiliated Hospital of Fujian Medical University, Longyan 364000, China. ²The Second School of Clinical Medicine, Southern Medical University, Guangzhou 510515, China. ³Department of Clinical Laboratory, Fujian Longyan First Hospital, Longyan First Affiliated Hospital of Fujian Medical University, Longyan 364000, China. ⁴Department of Endocrinology, Fujian Longyan First Hospital, Fujian Medical University, Fuzhou 350004, China. ⁵Department of Anesthesia, Fujian Longyan First Hospital, Longyan First Affiliated Hospital of Fujian Medical University, Longyan 364000, China.

Received: 29 October 2021 Accepted: 20 January 2022

Published online: 08 February 2022

References

- Beckman JA, Paneni F, Cosentino F, et al. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II. *Eur Heart J*. 2013;34(31):2444–52. <https://doi.org/10.1093/eurheartj/ehf142> (published Online First: 2013/04/30).
- Fayad ZA, Mani V, Fuster V. The time has come for clinical cardiovascular trials with plaque characterization as an endpoint. *Eur Heart J*. 2012;33(2):160–1. <https://doi.org/10.1093/eurheartj/ehf243> (published Online First: 2011/08/31).
- Avogaro A, Albiero M, Menegazzo L, et al. Endothelial dysfunction in diabetes: the role of reparatory mechanisms. *Diabetes Care*. 2011;34(Suppl 2):S285–90. <https://doi.org/10.2337/dc11-s239> (published Online First: 2011/05/06).
- Li L, Xie W, Zheng XL, et al. A novel peptide adropin in cardiovascular diseases. *Clin Chim Acta*. 2016;453:107–13. <https://doi.org/10.1016/j.cca.2015.12.010> (published Online First: 2015/12/20).
- Mushala BAS, Scott I. Adropin: a hepatokine modulator of vascular function and cardiac fuel metabolism. *Am J Physiol Heart Circ Physiol*. 2021;320(1):H238–44. <https://doi.org/10.1152/ajpheart.00449.2020> (published Online First: 2020/11/21).
- Gao S, McMillan RP, Zhu Q, et al. Therapeutic effects of adropin on glucose tolerance and substrate utilization in diet-induced obese mice with insulin resistance. *Mol Metab*. 2015;4(4):310–24. <https://doi.org/10.1016/j.molmet.2015.01.005> (published Online First: 2015/04/02).
- Kumar KG, Trevaskis JL, Lam DD, et al. Identification of adropin as a secreted factor linking dietary macronutrient intake with energy homeostasis and lipid metabolism. *Cell Metab*. 2008;8(6):468–81. <https://doi.org/10.1016/j.cmet.2008.10.011> (published Online First: 2008/12/02).
- Sato K, Yamashita T, Shirai R, et al. Adropin contributes to anti-atherosclerosis by suppressing monocyte-endothelial cell adhesion and smooth muscle cell proliferation. *Int J Mol Sci*. 2018. <https://doi.org/10.3390/ijms19051293> (published Online First: 2018/04/28).
- Yu HY, Zhao P, Wu MC, et al. Serum adropin levels are decreased in patients with acute myocardial infarction. *Regul Pept*. 2014;190–191:46–9. <https://doi.org/10.1016/j.regpep.2014.04.001> (published Online First: 2014/04/16).
- Wu L, Fang J, Chen L, et al. Low serum adropin is associated with coronary atherosclerosis in type 2 diabetic and non-diabetic patients. *Clin Chem Lab Med*. 2014;52(5):751–8. <https://doi.org/10.1515/cclm-2013-0844> (published Online First: 2013/12/11).
- Zhao LP, You T, Chan SP, et al. Adropin is associated with hyperhomocysteinemia and coronary atherosclerosis. *Exp Ther Med*. 2016;11(3):1065–70. <https://doi.org/10.3892/etm.2015.2954> (published Online First: 2016/03/22).
- Zhao LP, Xu WT, Wang L, et al. Serum adropin level in patients with stable coronary artery disease. *Heart Lung Circ*. 2015;24(10):975–9. <https://doi.org/10.1016/j.hlc.2015.03.008> (published Online First: 2015/04/29).
- Ozkan B, Orselik O, Yildirim Yaroglu H, et al. Association between serum adropin levels and isolated coronary artery ectasia in patients with stable angina pectoris. *Anatol J Cardiol*. 2019;22(5):250–5. <https://doi.org/10.14744/AnatolJCardiol.2019.90349> (published Online First: 2019/11/02).

14. Zheng J, Liu M, Chen L, et al. Association between serum adropin level and coronary artery disease: a systematic review and meta-analysis. *Cardiovasc Diagn Ther*. 2019;9(1):1–7. <https://doi.org/10.21037/cdt.2018.07.09> (publishedOnlineFirst:2019/03/19).
15. Fujie S, Hasegawa N, Sato K, et al. Aerobic exercise training-induced changes in serum adropin level are associated with reduced arterial stiffness in middle-aged and older adults. *Am J Physiol Heart Circ Physiol*. 2015;309(10):H1642–7. <https://doi.org/10.1152/ajpheart.00338.2015> (publishedOnlineFirst:2015/09/16).
16. Touboul PJ. Intima-media thickness of carotid arteries. *Front Neurol Neurosci*. 2015;36:31–9. <https://doi.org/10.1159/000366234> (publishedOnlineFirst:2014/12/23).
17. Li MF, Zhao CC, Li TT, et al. The coexistence of carotid and lower extremity atherosclerosis further increases cardio-cerebrovascular risk in type 2 diabetes. *Cardiovasc Diabetol*. 2016;15:43. <https://doi.org/10.1186/s12933-016-0360-2> (publishedOnlineFirst:2016/03/06).
18. Cardoso CRL, Leite NC, Moram CBM, et al. Long-term visit-to-visit glycaemic variability as predictor of micro- and macrovascular complications in patients with type 2 diabetes: The Rio de Janeiro Type 2 Diabetes Cohort Study. *Cardiovasc Diabetol*. 2018;17(1):33. <https://doi.org/10.1186/s12933-018-0677-0> (publishedOnlineFirst:2018/02/27).
19. Prati P, Tosetto A, Vanuzzo D, et al. Carotid intima media thickness and plaques can predict the occurrence of ischemic cerebrovascular events. *Stroke*. 2008;39(9):2470–6. <https://doi.org/10.1161/STROKEAHA.107.511584> (publishedOnlineFirst:2008/07/12).
20. Rundek T, Arif H, Boden-Albala B, et al. Carotid plaque, a subclinical precursor of vascular events: the Northern Manhattan Study. *Neurology*. 2008;70(14):1200–7. <https://doi.org/10.1212/01.wnl.0000303969.63165.34> (publishedOnlineFirst:2008/03/21).
21. Johnsen SH, Mathiesen EB, Joakimsen O, et al. Carotid atherosclerosis is a stronger predictor of myocardial infarction in women than in men: a 6-year follow-up study of 6226 persons: the Tromso Study. *Stroke*. 2007;38(11):2873–80. <https://doi.org/10.1161/STROKEAHA.107.487264> (publishedOnlineFirst:2007/09/29).
22. Xing L, Li R, Zhang S, et al. High burden of carotid atherosclerosis in rural Northeast China: a population-based study. *Front Neurol*. 2021;12: 597992. <https://doi.org/10.3389/fneur.2021.597992> (publishedOnlineFirst:2021/03/05).
23. Veeranna V, Zalawadiya SK, Niraj A, et al. Homocysteine and reclassification of cardiovascular disease risk. *J Am Coll Cardiol*. 2011;58(10):1025–33. <https://doi.org/10.1016/j.jacc.2011.05.028> (publishedOnlineFirst:2011/08/27).
24. Dong Y, Wang X, Zhang L, et al. High-sensitivity C reactive protein and risk of cardiovascular disease in China-CVD study. *J Epidemiol Community Health*. 2019;73(2):188–92. <https://doi.org/10.1136/jech-2018-211433> (publishedOnlineFirst:2018/12/12).
25. Butler AA, Tam CS, Stanhope KL, et al. Low circulating adropin concentrations with obesity and aging correlate with risk factors for metabolic disease and increase after gastric bypass surgery in humans. *J Clin Endocrinol Metab*. 2012;97(10):3783–91. <https://doi.org/10.1210/jc.2012-2194> (publishedOnlineFirst:2012/08/09).
26. Ganesh Kumar K, Zhang J, Gao S, et al. Adropin deficiency is associated with increased adiposity and insulin resistance. *Obesity* (Silver Spring, Md). 2012;20(7):1394–402. <https://doi.org/10.1038/oby.2012.31> (publishedOnlineFirst:2012/02/10).
27. Gu X, Li H, Zhu X, et al. Inverse correlation between plasma adropin and ET-1 levels in essential hypertension: a cross-sectional study. *Medicine*. 2015;94(40): e1712. <https://doi.org/10.1097/MD.0000000000001712> (publishedOnlineFirst:2015/10/09).
28. Sayin O, Tokgoz Y, Arslan N. Investigation of adropin and leptin levels in pediatric obesity-related nonalcoholic fatty liver disease. *J Pediatr Endocrinol Metab*. 2014;27(5–6):479–84. <https://doi.org/10.1515/jpem-2013-0296> (publishedOnlineFirst:2014/01/29).
29. Yu XH, Qian K, Jiang N, et al. ABCG5/ABCG8 in cholesterol excretion and atherosclerosis. *Clin Chim Acta*. 2014;428:82–8. <https://doi.org/10.1016/j.cca.2013.11.010> (publishedOnlineFirst:2013/11/21).
30. Lovren F, Pan Y, Quan A, et al. Adropin is a novel regulator of endothelial function. *Circulation*. 2010;122(11 Suppl):S185–92. <https://doi.org/10.1161/CIRCULATIONAHA.109.931782> (publishedOnlineFirst:2010/09/21).
31. Mottillo S, Filion KB, Genest J, et al. The metabolic syndrome and cardiovascular risk: a systematic review and meta-analysis. *J Am Coll Cardiol*. 2010;56(14):1113–32. <https://doi.org/10.1016/j.jacc.2010.05.034> (publishedOnlineFirst:2010/09/25).
32. Bozic J, Borovac JA, Galic T, et al. Adropin and inflammation biomarker levels in male patients with obstructive sleep apnea: a link with glucose metabolism and sleep parameters. *J Clin Sleep Med*. 2018;14(7):1109–18. <https://doi.org/10.5664/jcsm.7204> (publishedOnlineFirst:2018/07/12).
33. Yang M, Pei Q, Zhang J, et al. Association between adropin and coronary artery lesions in children with Kawasaki disease. *Eur J Pediatr*. 2021;180(7):2253–9. <https://doi.org/10.1007/s00431-021-03977-5> (publishedOnlineFirst:2021/03/14).

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

